CRISPR-Cas9 Disables Key Protein MADD, Suppressing Aggressive Thyroid Cancer

Anaplastic thyroid cancer (ATC) stands as one of the most aggressive and lethal malignancies, offering patients a grim prognosis and few effective treatment options. Prior research hinted at the importance of a protein called MADD (MAP-kinase-activating death domain-containing protein), with its selective downregulation increasing cancer cells' susceptibility to programmed cell death. However, the existence of multiple MADD gene isoforms created uncertainty about its definitive role, raising the possibility that other forms of the protein could compensate for its loss. To overcome this, researchers employed the precise gene-editing tool CRISPR-Cas9.

The study aimed to unequivocally determine MADD's function by targeting exon 3, a segment common to all known MADD isoforms, thereby achieving a complete functional knockout. When MADD was deleted using CRISPR-Cas9 in three distinct ATC cell lines, the results were striking: cancer cell viability plummeted, apoptosis (programmed cell death) increased significantly, cell migration was reduced, and cell division was arrested in the G0/G1 phase. Further RNA sequencing analysis confirmed broad alterations in genes vital for cell survival, proliferation, and metastasis, underscoring MADD's foundational role in these processes.

Moving beyond the petri dish, the team tested the impact of MADD deletion in an orthotopic ATC mouse model. The in vivo results echoed the in vitro findings, demonstrating a dramatic suppression of tumor growth, a significant reduction in lung metastases, and a prolonged survival for the mice. These consistent effects observed across multiple cell lines and living models provide compelling evidence that MADD plays a crucial role in ATC cell survival, proliferation, and metastasis.

Ultimately, these groundbreaking findings highlight MADD as a critical player in the pathogenesis of anaplastic thyroid cancer. As lead author Bakthavachalam notes in the paper, "The consistent effects observed across multiple cell lines and in vivo models suggest that MADD may represent a promising therapeutic target for this aggressive malignancy." Developing treatments that specifically inhibit MADD could offer a much-needed lifeline for patients battling this notoriously aggressive cancer, for which effective treatment options are currently limited.